Loading stock data…
ResMed Inc (RMD)
$228.35-0.84 (-0.37%)
Pre-Market$229.00+0.65 (+0.28%)· Last close Sep 4
ResMed Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ResMed Inc. in the Healthcare sector is trading at $228.35. Wall Street consensus targets $246.12 (16 analysts), implying a +7.8% move over the next 12 months. The stock is currently 20% below its 52-week high of $284.87, remaining 0.5% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +7.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.43B↑ | $1.42B↑ | $1.34B↓ | $1.35B↑ | $1.29B |
| Gross Profit | $890.98M↑ | $878.72M↑ | $820.82M | $820.07M↑ | $766.41M |
| Operating Income | $499.81M↑ | $497.60M↑ | $462.35M↑ | $456.57M↑ | $426.27M |
| Net Income | $398.73M↑ | $392.59M↑ | $348.54M↓ | $379.70M↑ | $365.04M |
Peer Comparison
JNJUNHPFE
Fundamentals
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorder...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.08%
ROE
Elite ROE. Management converts capital into profit efficiently.
17.56%
Volume
Today's trading volume
837,607
Recent News
2 Profitable Stocks Worth Investigating and 1 We Turn Down
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.
2 S&P 500 Stocks with Promising Prospects and 1 We Ignore
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
ResMed Stock: Analyst Estimates & Ratings
Although ResMed has underperformed the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.
ResMed’s (RMD) Sleep Business Booms Even As One Product Stumbles
On August 6, ResMed (NYSE:RMD) reported fourth-quarter fiscal 2026 results capping a year of double-digit growth. Quarterly revenue rose 9% to $1.5 billion, and non-GAAP earnings per share jumped 16% to $2.95. For the full fiscal year, which closed June 30, 2026, revenue grew 10%, and free cash flow topped $1.6 billion. The company also […]
The 5 Most Interesting Analyst Questions From ResMed’s Q2 Earnings Call
ResMed’s second quarter saw steady revenue growth, but the market responded negatively as the company’s operating margin declined year over year. Management attributed the margin compression primarily to higher R&D and supply chain costs amid inflation, despite continued demand for sleep devices and masks. CEO Mick Farrell pointed to ongoing investments in innovation and supply chain efficiency as both a necessity and a source of margin challenges. Additionally, ResMed took a $42 million charge